Addendum
Concizumab (haemophilia A, haemophilia B) – Addendum to Projects A25-55 and A25-56
Report documents
-
Addendum
Concizumab (haemophilia A, haemophilia B) – Addendum to Projects A25-55 and A25-56
Additional information
Federal Joint Committee (G-BA)
16-10-2025 A G-BA decision was published.
G-BA documents on this decision
Project details
- Project no.
- G25-27
- Commission
- Commission awarded on 09.09.2025 by the Federal Joint Committee (GBA).
- Report type
- Addendum
- Status
- Commission completed
- Department/Division
- Health Economics
- Topic
- Haematology
- Note
-
If, in the course of the discussions on a commission of the GBA, a need for further revision arises, IQWiG submits an addendum. The GBA decides on the number of patients in the SHI target population.
- DOI
https://doi.org/10.60584/G25-27
Connected Projects
-
Dossier assessment
Concizumab (haemophilia A) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Concizumab (haemophilia B) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed